	US 12,263,220 B2
	Compositions and methods for immunotherapy
Christopher C. Kloss, Philladelphia, PA (US); and Michel Sadelain, New York, NY (US)
Assigned to MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed by MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed on Jun. 13, 2023, as Appl. No. 18/333,753.
Application 16/847,059 is a division of application No. 14/676,255, filed on Apr. 1, 2015, granted, now 10,654,928, issued on May 19, 2020.
Application 18/333,753 is a continuation of application No. 16/847,059, filed on Apr. 13, 2020, granted, now 11,712,469.
Application 14/676,255 is a continuation of application No. PCT/US2013/063097, filed on Oct. 2, 2013.
Claims priority of provisional application 61/709,072, filed on Oct. 2, 2012.
Prior Publication US 2024/0091353 A1, Mar. 21, 2024
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 39/44 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 9/24 (2006.01)

CPC A61K 39/39558 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001102 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001113 (2018.08); A61K 39/001114 (2018.08); A61K 39/001117 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001128 (2018.08); A61K 39/001129 (2018.08); A61K 39/001153 (2018.08); A61K 39/001157 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/00117 (2018.08); A61K 39/001171 (2018.08); A61K 39/00118 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001193 (2018.08); A61K 39/001195 (2018.08); A61K 39/44 (2013.01); A61K 39/4611 (2023.05); A61K 39/464493 (2023.05); A61K 39/464495 (2023.05); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C12N 5/0638 (2013.01); C12N 9/2402 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01); C12N 2999/002 (2013.01)]

18 Claims

1. A method of producing an immunoresponsive cell or a pharmaceutical composition comprising the immunoresponsive cell, the method comprising introducing into the immunoresponsive cell:

a first nucleic acid molecule encoding a chimeric antigen receptor (CAR) that binds to a first antigen with a dissociation constant (Kd) of about 5×10⁻⁸M or more, wherein binding of the CAR to the first antigen is capable of delivering an activation signal to the immunoresponsive cell, and a second nucleic acid molecule encoding a chimeric co-stimulating receptor (CCR) that binds to a second antigen, wherein binding of the CCR to the second antigen is capable of delivering a costimulatory signal to the immunoresponsive cell but does not alone deliver an activation signal to the immunoresponsive cell;

wherein the immunoresponsive cell is capable of i) exhibiting negligible cytolytic activity against cells that are singly positive for the first antigen, and ii) inducing cytolytic activity against cells that are positive for both the first and second antigens.